|
B-Cell Lymphomas
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Additionally, it was observed that, when compared with Taxol treatment, the combination of Taxol and antagomiR-1207-5p induced a sharp decrease in B-cell lymphoma 2 (Bcl-2) and phosphorylated-protein kinase B expression accompanied by an increase in the Bcl-2-associated X protein expression.
|
30655858 |
2019 |
|
B-Cell Lymphomas
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Furthermore, icariin elevated the expression levels of AKT, phosphorylation-akt (p-AKT), PI3K (110 kDa), PI3K (85 kDa), and B-cell lymphoma 2 (Bcl-2) in the ovaries, and inhibited those of Bax.
|
31618892 |
2019 |
|
B-Cell Lymphomas
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Furthermore, miR-183 downregulation led to significant decreases in the mRNA levels of PI3K, Akt and B cell lymphoma-2 (Bcl-2) expression (P<0.001), and significant increases in PTEN and Bcl-2 associated X protein expression in PANC-1 cells (P<0.001).
|
30783438 |
2019 |
|
B-Cell Lymphomas
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Western blot assay was also used to measure the protein levels of B‑cell lymphoma 2 (Bcl‑2), Bcl‑2‑associated death promoter (Bad), total protein kinase B (Akt), phospho‑Akt and caspase‑3/9.
|
30864701 |
2019 |
|
B-Cell Lymphomas
|
0.100 |
Biomarker
|
group |
BEFREE |
Moreover, cinobufagin clearly inhibited the levels of phosphoinositide 3-kinase (PI3K), phosphorylated PI3K (p-PI3K), AKT, p-AKT, and B-cell lymphoma 2 (Bcl-2).
|
31552178 |
2019 |
|
B-Cell Lymphomas
|
0.100 |
AlteredExpression
|
group |
BEFREE |
MANF was mainly expressed in rat neurons, and its expression increased significantly at 3 h after SAH induction and peaked at 24 h. Stereotactic injection of rh-MANF into the cerebroventricle significantly increased the level of MANF, p-Akt, p-mouse double minute 2 homolog (p-MDM2), and B-cell lymphoma 2 (Bcl-2) in brain tissue, whereas it down-regulated the expression of P53, Bcl-2-associated X protein (Bax), and cleaved caspase-3, which indicated that neuronal apoptosis was remarkably suppressed.
|
30211660 |
2019 |
|
B-Cell Lymphomas
|
0.100 |
AlteredExpression
|
group |
BEFREE |
CM-FDMSC-treated A375 cells showed decreased phosphatidylinositol 3-kinase (PI3K), protein kinase B (AKT), and extracellular signal-regulated kinase (ERK) phosphorylation, and up-regulation of Bcl-2-Associated X (BAX) and down-regulation of B-cell lymphoma-2 (BCL-2) expression.
|
31239698 |
2019 |
|
B-Cell Lymphomas
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Moreover, silencing of Akt1 and 2 isoforms was found to decrease the expression of proteins regulating cancer cell survival and proliferation such as cyclooxygenase-2, B-cell lymphoma 2 (Bcl-2), cyclin D1, and survivin.
|
31252679 |
2019 |
|
B-Cell Lymphomas
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In addition, MT treatment protected kidney tissue against oxidative damages and significantly upregulated the expression level of Klotho decreased by CP treatment, resulting in reduced phosphorylation of protein kinase B (AKT) and forkhead box O (FOXO) as well as reduced expression levels of B-cell lymphoma 2-associated X protein (Bax) and caspase-3.
|
31039387 |
2019 |
|
B-Cell Lymphomas
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Immunoblotting results showed that maltol pretreatment downregulated the protein expression levels of the B-cell-lymphoma-2 (Bcl-2) family and caspase and altered the phosphorylation of phosphatidylinositol 3-kinase/protein kinase B (PI3K/Akt) in a dose-dependent manner.
|
31547366 |
2019 |
|
B-Cell Lymphomas
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Furthermore, the expression of B‑cell lymphoma 2 and phosphorylated‑protein kinase B (p‑Akt) decreased.
|
30942438 |
2019 |
|
B-Cell Lymphomas
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Following treatment with FA for 24 h, cell viability, the cell cycle, apoptosis, and the expression of PTEN, PI3K and Akt, as well as the protein expression of B‑cell lymphoma 2 (Bcl‑2), Bcl‑2‑associated X (Bax), and Caspases‑3 and ‑9 were examined.
|
31115571 |
2019 |
|
B-Cell Lymphomas
|
0.100 |
AlteredExpression
|
group |
BEFREE |
By the western blotting analysis, FXS-3 increased the expression of B-cell lymphoma-2 (Bcl-2) associated X protein (Bax)/Bcl-2 ratio, inhibited matrix metalloproteinase (MMP)-2 and MMP-9, and regulated the extracellular signal-regulated kinase (ERK)/p38, c-Jun N-terminal kinase (JNK), protein kinase B (AKT)/mechanistic target of rapamycin (mTOR), as well as mitogen-activated protein kinase (MEK)/ERK signaling pathways.
|
31181779 |
2019 |
|
B-Cell Lymphomas
|
0.100 |
PosttranslationalModification
|
group |
BEFREE |
The effects of IS on cell viability were determined using MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assays and levels of apoptosis-related proteins (Bcl-2-associated protein X [Bax] and B-cell lymphoma 2 [Bcl-2]), nuclear factor-κB (NF- κB) p65, and phosphorylation of mitogen-activated protein kinase (MAPK) and protein kinase B (Akt) were determined by semiquantitative immunoblotting.
|
28992684 |
2019 |
|
B-Cell Lymphomas
|
0.100 |
Biomarker
|
group |
BEFREE |
Inhibitors of the PI3K/AKT pathway have been approved for the treatment of refractory indolent B-NHL and continue to be investigated for treatment of aggressive B-NHLs.
|
29774105 |
2018 |
|
B-Cell Lymphomas
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Also, SJWE inhibited the phosphorylation of protein kinase B (Akt) and showed increases in the expression of pro-apoptotic proteins Bax and Bad with decreases in the expression of anti-apoptotic proteins including B-cell lymphoma 2 (Bcl-2), B-cell lymphoma-extra large (Bcl-xL), and p-Bcl-2-associated death promoter (p-Bad).
|
29570671 |
2018 |
|
B-Cell Lymphomas
|
0.100 |
Biomarker
|
group |
BEFREE |
Alteration to down-stream signaling of p53 including activation of pro-apoptosis protein (Bcl-2-associated X protein; Bax), reduction of anti-apoptosis (B cell lymphoma 2; Bcl-2 and myeloid cell leukemia 1; Mcl-1) and suppression on protein kinase B (Akt) survival pathway were notified in TDB-treated lung cancer cells.
|
29488156 |
2018 |
|
B-Cell Lymphomas
|
0.100 |
AlteredExpression
|
group |
BEFREE |
STZ treatment led to significant decrease in phospho-AMP-activated protein kinase (p-AMPK) level; reduction in levels of phospho-protein kinase R-like endoplasmic reticulum kinase (PERK) and inositol-requiring enzyme 1α (IRE1α); significant reduction in levels of p85α, p110, phospho-serine and threonine kinase/protein kinase B (p-Akt/PKB) (Ser473), phospho-extracellular-regulated kinase (p-ERK), and phospho-mammalian target of rapamycin (p-mTOR); increase in levels of Cu/Zn-superoxide dismutase (SOD), Mn-SOD, and catalase; decrease in B-cell lymphoma 2 (Bcl-2) expression; increase in Bcl-2-associated X protein (Bax) expression; increase in levels of microtubule-associated protein 1 light chain 3 (LC3) and Beclin 1; and reduction in production of intracellular insulin.
|
29485914 |
2018 |
|
B-Cell Lymphomas
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Protein expression levels, including B cell lymphoma-2 (Bcl-2), Bcl-2 associated X protein, E- and N-cadherin, snail, vimentin, phosphatase and tensin homolog (PTEN) and protein kinase B (AKT) were examined by western blotting.
|
30344696 |
2018 |
|
B-Cell Lymphomas
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Finally, the effects of HSPA12B overexpression on the phosphorylation of protein kinase B (Akt) and nuclear factor-κB inhibitor α (IκBα), and the expression of the anti-apoptotic protein B-cell lymphoma 2 (Bcl-2) and the pro-apoptotic protein cleaved caspase-3 were determined by western blot analysis.
|
29556279 |
2018 |
|
B-Cell Lymphomas
|
0.100 |
PosttranslationalModification
|
group |
BEFREE |
Decreased chemosensitivity to cisplatin may be associated with increased expression of phosphorylated-protein kinase B and cyclin dependent kinase 2 and with decreased expression of p21 and the B cell lymphoma (Bcl)-2 associated X/Bcl-2 ratio.
|
29928364 |
2018 |
|
B-Cell Lymphomas
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Furthermore, the protein levels of phosphorylated‑protein kinase B (Akt), B‑cell lymphoma‑2 (Bcl‑2), Bcl‑2‑associated X (Bax), caspase‑3 and caspase‑9 were investigated by western blotting.
|
29257286 |
2018 |
|
B-Cell Lymphomas
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Sal decreased the expression of cleaved caspase-3, cleaved caspase‑9, apoptosis regulator BAX and cytochrome C, while it increased the expression of B cell lymphoma‑2 and phosphorylated‑Akt in Dex‑induced osteoblasts.
|
29286130 |
2018 |
|
B-Cell Lymphomas
|
0.100 |
Biomarker
|
group |
BEFREE |
The effect of combined treatment on the concentration of selected markers of apoptosis including proapoptotic B-cell lymphoma 2 associated X protein (Bax), caspase-8, cytochrome <i>c</i> and caspase-9, as well as selected proteins involved in intracellular signal transduction pathways including p53, phosphoinositide 3-kinase and phosphorylated protein kinase B (p-Akt) were analyzed.
|
29434943 |
2018 |
|
B-Cell Lymphomas
|
0.100 |
Biomarker
|
group |
BEFREE |
The levels of B-cell lymphoma 2 (Bcl-2), Bcl-2-associated X protein, phospho (p)-protein kinase B (Akt), Akt, p-glycogen synthase kinase (GSK)-3β and GSK-3β were evaluated using western blotting.
|
30210588 |
2018 |